ClinicalTrials.gg
TerminatedNCT00784836Updated May 7, 2014Results posted

Immunogenicity and Safety of Subcutaneously-administered Avonex (Interferon Beta-1a) in Multiple Sclerosis (MS) Patients

A Phase 3 interventional study of BG9418 (interferon beta 1-a) in Multiple Sclerosis, sponsored by Biogen. Terminated at 2 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-05-07.

Sponsored by Biogen · Phase 3, Interventional, and Treatment

Why this study was terminated
Terminated early by Sponsor for business reasons unrelated to safety.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing Interferon beta-1a in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis.

Enrollment
32nd of 34
3 · median 85
Started
2008
with 1 other
Phase 3
7 of 34
none open now
Registered
14th of 34
by date
Lead sponsor
15 of 34
Biogen

Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, this one is the 32nd largest by enrollment, is one of 2 that started in 2008, is one of 7 in phase 3, and was the 14th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

None of the 34 studies testing Interferon beta-1a in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 34 studies testing Interferon beta-1a in Multiple Sclerosis as a file.
02

Study summary

The primary objective of the study was to evaluate the immunogenicity of Avonex® (interferon beta-1a) 30 mcg when administered subcutaneously (SC) to interferon-naïve participants with relapsing multiple sclerosis. The secondary objective of this study was to evaluate the safety and tolerability of Avonex® 30 mcg when administered SC to interferon-naïve subjects with relapsing MS.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • Multiple Sclerosis - Relapsing
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to understand the purpose and risks of the study and provide signed and dated and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
  • Male or female aged 18- to 60-years-old, inclusive, at the time of informed consent.
  • Must have a diagnosis of relapsing MS.
  • Must have a screening Expanded Disability Status Scale (EDSS) score between 0 and 6.0, inclusive.
  • All male subjects and female participants of must practice effective during the study and be willing and able to continue contraception for 30 days after their last study dose of Avonex.

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic or anaphylactic reactions.
  • Diagnosed with Primary progressive, secondary progressive, or progressive relapsing MS.
  • Known allergy to any component of the Avonex formulation.
  • History of any (as determined by the investigator) cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric renal, or other major disease.
  • Subjects with history of malignant disease, including solid tumors and hematologic .
  • History of seizure disorder or unexplained blackouts OR history of a seizure within 3 months prior to Day 1.
  • History of suicidal ideation within 3 months prior to Day 1 or an episode of severe depression within 3 months prior to Day 1. Severe depression is defined as any episode of depression that requires hospitalization, or the initiation of antidepressant therapy, or an increase in the dose of an existing regimen of antidepressant therapy.
  • Clinically significant abnormal (ECG) values as determined by the investigator.
  • Known history of, or a positive test result for, (HIV).
  • Known history of, or a positive test result for virus.
  • Abnormal screening blood tests exceeding any of the limits defined below:

    1. /serum glutamate pyruvate transaminase (ALT/SGPT) greater than 2 times the or aspartate transaminase/serum glutamic oxaloacetic transaminase or .
    2. Total white blood cell count (WBC) \<3700 cells/mm
    3. count \<150,000 cells/mm
    4. \<10 g/dL in female subjects; \<11 g/dL in male subjects
    5. Serum creatinine >upper limit of normal (ULN)
    6. (PT) or activated partial thromboplastin time (aPTT) > 1.2*ULN
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Avonex

    Avonex 30 mcg given subcutaneously, once weekly, for 18 months.

    Drug: BG9418 (interferon beta 1-a)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Developed Neutralizing Antibodies (NAbs) to Interferon-beta (IFN-beta)

    The presence of antibodies to IFN-beta in human serum, determined using a tiered approach involving a screening Enzyme-Linked ImmunoSorbent Assay (ELISA) to detect binding antibodies (BAbs). Positive samples characterized and titrated in a cell-based neutralizing antibody (NAb) assay.

    Time frame: assessed every 3 months up to 18 months

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not related to the investigational product. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the investigator, places the participant at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or results in a congenital anomaly/birth defect. An SAE may also be any other medically important event that, in the opinion of the investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above.

    Time frame: Planned for up to 18 months plus 30 days; actual study duration was 111 days.

07

Results

Posted May 7, 2014
Limitations and caveats
Early termination with partial data from 3 subjects, therefore, no statistical analysis performed.

Participant flow

Participant flow — Overall Study
MilestoneAvonex
Started3
Completed0
Not completed3
Withdrew: Early study termination3

Outcome measures

PrimaryNumber of Participants Who Developed Neutralizing Antibodies (NAbs) to Interferon-beta (IFN-beta)

The presence of antibodies to IFN-beta in human serum, determined using a tiered approach involving a screening Enzyme-Linked ImmunoSorbent Assay (ELISA) to detect binding antibodies (BAbs). Positive samples characterized and titrated in a cell-based neutralizing antibody (NAb) assay.

Time frame:
assessed every 3 months up to 18 months

No measurements were reported for this outcome.

SecondaryNumber of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

AE: any untoward medical occurrence in a participant that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product, whether or not related to the investigational product. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the investigator, places the participant at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or results in a congenital anomaly/birth defect. An SAE may also be any other medically important event that, in the opinion of the investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above.

Time frame:
Planned for up to 18 months plus 30 days; actual study duration was 111 days.
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsAvonex
AEs3
SAEs0

Adverse events

Collected over Planned for up to 18 months plus 30 days; actual study duration was 111 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Avonex—0/3 (0%)3/3 (100%)
Most frequent other events
Most frequent other events
EventAvonex
Influenza like illnessGeneral disorders2/3
Injection site reactionGeneral disorders1/3
Hepatic enzyme increasedInvestigations1/3

Baseline characteristics

Age, Customized
Age, Customized(participants)Avonex
<=18 years0
Between 18 and 60 years3
> 60 years0
Sex: Female, Male
Sex: Female, Male(Participants)Avonex
Female2
Male1
08

Study locations

2 sites
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • MS Center at Texas Neurology
    Dallas, Texas 75214, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 5 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2008
First posted
Nov 4, 2008
Start
Oct 2008
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
May 7, 2014
Last update
May 7, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00784836
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Nov 4, 2008
Start date
Oct 2008
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
May 7, 2014
Last update
May 7, 2014

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion